RE:RE:bought back for cancellation ... 633,150 sharesgudisgood wrote: MrMugsy wrote: d 2022-02-08 17:31 Tx date 2022-01-31 | $GUD Knight Therapeutics Inc. | Knight Therapeutics Inc. 1 - Issuer Direct Ownership | Common Shares 38 - Redemption, retraction, cancellation, repurchase | -633,150 vol | 0 |
I believe we should be close to 117M shares outstanding. Maybe essentially there already if buybacks continued similarly in February.
IF we get $10M in cash inflow from operations for Q4 (I have no idea if this is going to happen as there are too many unknown factors, and it's relatively meaningless in the long run), it's $50M for the whole year, and that's around $0.42 per share (current shares outstanding), for a company with a porftolio of growing products, growing market, and in general is essentially "just getting started".
Cash inflow was a
negative $17M in 2020 if my numbers are correct.
Add to that $1.28 per share in cash and marketable securities. I like where we are right now. :)
FWIW ...
Cashflow for 2020 as shown in the annual report on page 23 (YTD numbers)
1. negative $12.2M in cash from operations
2. positive $101.353M in cash from investing
3. negative $29.2333M in cash used in financing
Total cashflow of positive $59.915M